Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma

Clinical Endocrinology

Volumn 68, Issue 4, 2008, Pages 605-609

  Liu, Ying Y ^a   Stokkel, Marcel P ^a   Morreau, Hans A ^a   Pereira, Alberto M ^a   Romijn, Johannes A ^a   Smit, Johannes W A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; IODINE 131; RADIOACTIVE IODINE; RECEPTOR SUBTYPE; RETINOID X RECEPTOR; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTICARCINOGENIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; TETRAHYDRONAPHTHALENES; THYROGLOBULIN; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 40749092848     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03096.x     Document Type: Article

References (24)

1. Arturi, F., Russo, D., du Schlumberger, M.V.J., Caillou, B., Vigneri, P., Wicker, R., Chiefari, E., Suarez, H.G. Filetti, S. (1998) Iodide symporter gene expression in human thyroid tumors. Journal of Clinical Endocrinology and Metabolism, 83, 2493 2496.
2. Caillou, B., Troalen, F., Baudin, E., Talbot, M., Filetti, S., Schlumberger, M. Bidart, J.M. (1998) Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. Journal of Clinical Endocrinology and Metabolism, 83, 4102 4106.
3. Lazar, V., Bidart, J.M., Caillou, B., Mahe, C., Lacroix, L., Filetti, S. Schlumberger, M. (1999) Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism, 84, 3228 3234.
4. Havekes, B., Schroder Van Der Elst, J.P.P.G., Goslings, B.M., Romijn, J.A. Smit, J.W. (2000) Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines. Journal of Endocrinology, 167, 229 238.
5. Schmutzler, C., Brtko, J., Bienert, K. Kohrle, J. (1996) Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Experimental and Clinical Endocrinology and Diabetes, 104 (Suppl. 4 16 19.
6. Schmutzler, C. Kohrle, J. (2000) Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid, 10, 393 406.
7. Van Herle, A.J., Agatep, M.L., Padua, D.N. III., Totanes, T.L., Canlapan, D.V., Van Herle, H.M. Juillard, G.J. (1990) Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. Journal of Clinical Endocrinology and Metabolism, 71, 755 763.
8. Schmutzler, C., Schmitt, T.L., Glaser, F., Loos, U. Kohrle, J. (2002) The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Molecular and Cellular Endocrinology, 189, 145 155.
9. Coelho, S.M., Corbo, R., Buescu, A., Carvalho, D.P. Vaisman, M. (2004) Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. Journal of Endocrinological Investigation, 27, 334 339.
10. Short, S.C., Suovuori, A., Cook, G., Vivian, G. Harmer, C. (2004) A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clinical Oncology (Royal College of Radiology), 16, 569 574.
11. Simon, D., Koehrle, J., Reiners, C., Boerner, A.R., Schmutzler, C., Mainz, K., Goretzki, P.E. Roeher, H.D. (1998) Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World Journal of Surgery, 22, 569 574.
12. Simon, D., Kohrle, J., Schmutzler, C., Mainz, K., Reiners, C. Roher, H.D. (1996) Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Experimental and Clinical Endocrinology and Diabetes, 104 (Suppl. 4 13 15.
13. Simon, D., Korber, C., Krausch, M., Segering, J., Groth, P., Gorges, R., Grunwald, F., Muller-Gartner, H.W., Schmutzler, C., Kohrle, J., Roher, H.D. Reiners, C. (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 29, 775 782.
14. Smith, M.A., Parkinson, D.R., Cheson, B.D. Friedman, M.A. (1992) Retinoids in cancer therapy. Journal of Clinical Oncology, 10, 839 864.
15. Elisei, R., Vivaldi, A., Agate, L., Ciampi, R., Molinaro, E., Piampiani, P., Romei, C., Faviana, P., Basolo, F., Miccoli, P., Capodanno, A., Collecchi, P., Pacini, F. Pinchera, A. (2005) All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism, 90, 2403 2411.
16. Haugen, B.R., Larson, L.L., Pugazhenthi, U., Hays, W.R., Klopper, J.P., Kramer, C.A. Sharma, V. (2004) Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. Journal of Clinical Endocrinology and Metabolism, 89, 272 280.
17. Farol, L.T. Hymes, K.B. (2004) Bexarotene: a clinical review. Expert Review of Anticancer Therapy, 4, 180 188.
18. Lowe, M.N. Plosker, G.L. (2000) Bexarotene. American Journal of Clinical Dermatology, 1, 245 250.
19. Rigas, J.R. Dragnev, K.H. (2005) Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist, 10, 22 33.
20. Liu, Y.Y., Stokkel, M.P., Pereira, A.M., Corssmit, E.P., Morreau, H.A., Romijn, J.A. Smit, J.W. (2006) Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. European Journal of Endocrinology, 154, 525 531.
21. Sherman, S.I. (2003) Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clinical Lymphoma, 3, 249 252.
22. Pluijmen, M.J., Eustatia-Rutten, C., Goslings, B.M., Stokkel, M.P., Arias, A.M., Diamant, M., Romijn, J.A. Smit, J.W. (2003) Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinology, 58, 428 435.
23. Maxon, H.R. III., Englaro, E.E., Thomas, S.R., Hertzberg, V.S., Hinnefeld, J.D., Chen, L.S., Smith, H., Cummings, D. Aden, M.D. (1992) Radioiodine-131 therapy for well-differentiated thyroid cancer: a quantitative radiation dosimetric approach: outcome and validation in 85 patients. Journal of Nuclear Medicine, 33, 1132 1136.
24. Dohan, O., Baloch, Z., Banrevi, Z., LiVolsi, V. Carrasco, N. (2001) Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. Journal of Clinical Endocrinology and Metabolism, 86, 2697 2700.